Homocysteine relations with ischemic vascular diseases;L'homocystéine : Ses liens avec les maladies cardiovasculaires ischémiques

Revue de Medecine Interne

Volumn 17, Issue 1, 1996, Pages 34-45

  Piolot, A ^a   Nadler, F ^a   Parez, N ^a   Jacotot, B ^a  

^a NONE

Author keywords

Cardiovascular risk factors; Folic acid; Homocysteine atherosclerosis; Vitamin B6

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ANTICOAGULATION; ATHEROSCLEROSIS; DISEASE ASSOCIATION; FIBRINOLYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK FACTOR; ARTERIOSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; HEART MUSCLE ISCHEMIA; METABOLISM; PATHOPHYSIOLOGY; URINE;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0029671240     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)88394-9     Document Type: Article

References (143)

1. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic basis of inherited disease, 6th ed. New York: McGraw-Hill, 1989;693
2. Skovby F. Inborn errors of metabolism causing homocysteinemia and related vascular involvement. Haemostasis 1989;19(Suppl 1):4-9
3. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease; plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501
4. Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1-31
5. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3
6. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma. Anal Biochem 1992;200:218-29
7. Refsum H, Helland S, Ueland PM. Radioenzymatic determination of homocysteine in plasma and urine. Clin Chem 1985;31:624-8
8. Wiley VC, Dudman NPB, Wilcken DEL. Interrelations between plasma free and protein-bound homocysteine and cysteine in homocystinuria. Metabolism 1988;37:191-5
9. Stabler SP, Marcell PD, Podell ER, Allen RH. Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 1987;162:185-96
10. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991;69:527-34
11. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum; methods and clinical applications. Clin Chem 1993;39:1764-79
12. Reed MM, Rodgers GM. Homocysteinemia; association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59
13. Clarke R, Daly I, Robinson K et al. Hyperhomocysteinemia; an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55
14. Brattström L, Israelsson B, Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 1989;19(Suppl 1):35-44
15. Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-33
16. Murphy Chutorian DR, Wesman MP, Grieco AJ et al. Methionine intolerance;a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985;6:725-30
17. Boers GHJ, Smals AGH, Trijbels FJM et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15
18. Satdharwalla IB, Fowla B, Robins AJ, Komrower GM. Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading. Arch Dis Child 1971;49:553-9
19. Brattström L, Israelsson B, Horrving B et al. Impaired homocysteine metabolism in early onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60
20. Andersson A, Brattström L, Israelsson B, Isaksson A, Hultberg B. The effect of excess daily methionine intake on plasma homocysteine after a methionine loading test in humans. Clin Chim Acta 1990;192:69-76
21. Goldstein IL, Campbell BK, Gartler SM. Homocystinuria: heterozygote detection using phytohemagglutinin-stimulated lymphocytes. J Clin Invest 1973;52:218-21
22. Pancharuniti N, Lewis CA, Sauberlich HE et al. Plasma homocysteine folate and vitamin B-12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr 1994;59:940-8
23. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurence, cofactor therapy, and enzymology. Arteroscler Thromb 1993;13:1253-60
24. Taylor LM Jr, Defrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36
25. Genest J Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary arterial disease. J Am Coll Cardiol 1990;16:1114-9
26. Malinow MR, Kang SS, Taylor LM et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8
27. Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in isthemic heart disease. Atherosclerosis 1988;69:109-13
28. Kang SS, Wong PWK, Cool HY, Norusis M, Messer JV. Protein bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-6
29. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-70
30. van den Berg M, Galema TW de Haan J et al. Exercise-induced silent myocardial ischemia in healthy individuals with mild hyperhomocysteinemia [Abstract]. Circulation 1994;I-559
31. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A posible role for methionine metabolism. J Clin Invest 1976;57:1079-81
32. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-13
33. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465-70
34. Brattström L, Lindgren A, Israelsson B et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-21
35. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-6
36. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989;79:139-46
37. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995;15:232-40
38. Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischemia below the age of 50: effect of smoking and extent of disease. Eur J Vasc Surg 1993;7:391-6
39. Mölgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inemia; an independent risk factor for intermittent claudication. J Intern Med 1992;231:273-9
40. von Eckardstein A, Malinow MR, Upson B et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:460-4
41. Wu LL, Wu J, Hunt SC et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61
42. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91
43. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophtalmol 1993;115:162-7
44. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19
45. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81
46. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-30
47. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991;21:51-7
48. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993;70:123-9
49. den Heijer M., Blom HJ, Gerrits WBJ et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5
50. Munnich A, Saudubray JM, Dautzenberg MD et al. Diet-responsive proconvertin (factor VII) deficiency in homocystinuria. J Pediatr 1983;102:730-4
51. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia; vascular injury and thrombosis. N Engl J Med 1974;291:537-43
52. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8
53. Kang SS, Wong PWK, Zhou J et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988;37:611-3
54. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5
55. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol; modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24
56. Midander J, Deschavanne PJ, Debieu D, Malaise EP, Revesz L. Reduced repair of potentially lethal radiation damage in glutathione synthetase-deficient human fibroblasts after X-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 1986;49:403-13
57. Wellner VP, Anderson ME, Puri RN, Jensen GL, Meister A. Radioprotection by glutathione ester: transport of glutathione ester into human lymphoid cells and fibroblasts. Proc Natl Acad Sci USA 1984;81:4732-5
58. Arrick BA, Nathan CF, Griffith OW, Cohn ZA. Glutathione depletion sensitizes tumor cells to oxidative cytolysis. J Biol Chem 1982;257:1231-7
59. Jialal I, Grundy SM. Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest 1991;87:597-601
60. Schöneich C, Dillinger U, von Bruchhausen F, Asmus KD. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals; reaction kinetics and influence of oxygen and structure of thiyl radicals. Arch Biochem Biophys 1992;292:456-67
61. Miller DM, Buettner GR, Aust SD. Transition metals as catalysts of autoxidation reactions. Free Radic Biol Med 1990;8:95-108
62. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987;97:337-40
63. Harman LS, Carver DK, Schreiber J, Mason RP. One- and two-electron oxidation of reduced glutathione by peroxidases. J Biol Chem 1986;261:1642-8
64. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6
65. Van Steveninck J, Van Der Zee J, Dubbelman TM. Site-specific and bulk-phase generation of hydroxyl radicals in the presence of cupric ions and thiol compounds. Biochem J 1985;232:309-11
66. Saez G, Thornalley PJ, Hill HAO, Hems R, Bannister JV. The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta 1982;719:24-31
67. Quintiliani M, Badiello R, Tamba M, Esfandi A, Gorin G. Radiolysis of glutathione in oxygen-containing solutions of pH 7. Int J Radiat Biol Relat Stud Phys Chem Med 1977;32:195-202
68. Misra HP. Generation of superoxide free radical during the autoxidation of thiols. J Biol Chem 1974;249:2151-5
69. Sparrow CP, Olszewski J. Cellular oxidation of low density lipoproteins is caused by thiol production in media containing transition metal ions. J Lipid Res 1993;34:1219-28
70. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103
71. Schöneich C, Asmus KD, Dillinger U, von Bruchhausen F. Thiyl radical attack on polyunsaturated fatty acids: a possible route to lipid peroxidation. Biochem Biophys Res Commun 1989;161:113-20
72. Harman LS, Mottley C, Mason RP. Free radical metabolites of L-cysteine oxidation. J Biol Chem 1984;259:5606-11
73. Martin WJ. Neutrophils kill pulmonary endothelial cells by a hydrogen-peroxide-dependent pathway: an in vitro model of neutrophil-mediated lung injury. Am Rev Resp Dis 1984;130:209-13
74. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacobs HS. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest 1978;61:1161-7
75. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988;255:H1269-75
76. Ross R. The pathogenesis of atherosclerosis; an update. N Engl J Med 1986;314:488-500
77. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol 1986;48:721-31
78. Weiss SJ, Young J, LoBuglio AF, Slivka A, Nimek NF. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981;68:714-21
79. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and-independent mechanisms. J Lipid Res 1993;34:2051-61
80. Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994;105:165-70
81. Hirano K, Ogihara T, Miki M et al. Homocysteine induces iron-catalyzed lipid peroxidation of low density lipoprotein that is prevented by alpha tocopherol. Free Radical Res 1994;21:267-76
82. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis. J Clin Invest 1976;58:731-41
83. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113-21
84. Berman RS, Martin W. Arterial endothelial barrier dysfunction; actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 1993;108:920-6
85. Dudman NP, Hicks C, Wang J, Wilcken DE. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991;91:77-83
86. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992;94:89-91
87. Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1976;91:308-18
88. Stamler JS, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovascular Pharmacol 1992;20:S202-4
89. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993;81:683-9
90. Wang J, Dudman NP, Wilcken DE. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993;70:1047-52
91. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenicst and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193
92. Lai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73
93. Ross R. The pathogenesis of atherosclerosis;a perspective for the 1990s. Nature 1993;362:801-9
94. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14
95. Rodgers GM, Cohn MT. Homocysteine, an atherogenic stimulus reduces protein C activation by arterial and venous endothelial cells. Blood 1990:75:895-901
96. Hayashi L, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-6
97. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent suppressed anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-6
98. Bienvenu T, Chadefaux B, Ankri A et al. Antithrombin III activity is not related to plasma homocysteine concentrations. Haemostasis 1991;21:65
99. Fryet RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine a risk factor for premature vascular disease and thrombosis induces tissue factor activity in endothethelial cells. Arterioscler Thromb 1993;13:1327-33
100. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16
101. Hajjar KA. Homocysteine induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9
102. Reed I, Malinow MR, Christian JC, Upson B. Estimates of heritability of plasma homocyst(e)ine levels in aging adult male twins. Clin Genet 1991;39:425-8
103. Mudd SH, Havlik R, Lett HL, McKusick VA, Feinleib MA. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981;33:883-93
104. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase;an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;18:536-45
105. Genest J Jr, Lussier-Cacan S, Davignon J, Latour Y, Selhub J. Homocyst(e)ine in health and coronary artery disease in French Canadian men and women relationship with vitamins B12, B6, pytidoxal phosphate and folate. Atherosclerosis [Abstract]. 1994:109-18
106. Jacobson DW, Gatautis SL, Green R et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81
107. Jacob RA, Wu MM, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 1994;124:1079-80
108. Nilsson K, Gustalson I, Fäldt R, Andersson A, Hultberg B. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994;21:600-6
109. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamn B-6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nut 1993;57:47-53
110. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87
111. Mason JB, Miller JW. The effects of vitamins B12, B6, and folate on blood homocysteine levels. In: Sauberlich HE, Machlin LJ, eds. Beyond deficiency: new views on the function and health effects of vitamins. New York: The New York Academy of Sciences, 1992:360
112. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988;81:466-74
113. Brattström L, Israelsson B, Lindgärde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism 1988;37:175-8
114. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-62
115. Smolin LA, Benevenga NJ. Accumulation of homocyst(e)ine in vitamin B6 deficiency: a model for the study of cystathionine beta-synthase deficiency. J Nutr 1982;112:1264-272
116. Miller JW, Ribaya-Mercado JD, Russel RM et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992;55:1154-60
117. Shin HK, Linkswiler HM. Tryptophan and methionine metabolism of adult females is affected by vitamin B-6 deficiency. J Nutr 1974;104:1348-55
118. Park YK, Linkswiler H. Effect of vitamin B6 depletion in adult man on the excretion of cystathionine and other methionine metabolites. J Nutr 1970;100:110-6
119. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301-7
120. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;3:230-5
121. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;41(Suppl):S72-7
122. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insuffisiency: possible implications for prevention of vascular disease. Metabolism 1988;37:697-701
123. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993;17:687-9
124. Brattström LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;34:1073-7
125. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-6
126. Andersson A, Hultberg B, Brattström L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30:377-9
127. Kang SS, Wong PWK, Zhou J, Cook HY. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 1986;35:889-91
128. Steegers-Theunissen RPM, Boers GHJ, Steegers EAP, Trijbels FJM, Thomas CMG, Eskes TKAB. Effects of sub-50 oral contraceptives on homocysteine metabolism:a preliminary study. Contraception 1992;45:129-39
129. Brattström L, Israelsson B, Olsson A, Andersson A, Hultberg B. Plasma homocysteine in women on oral estrogen-containing contraceptives and in men with estrogen-treated prostatic carcinoma. Scand J Clin Lab Invest 1992;52:283-7
130. Beaumont V, Malinow MR, Sexton G et al. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis 1992;94:147-52
131. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993;103:149-57
132. Hultberg B, Agardh E, Andersson A et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Invest 1991;51:277-82
133. Blankenhorn DH, Malinow MR, Mack WJ. Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Artery Dis 1991;2:357-60
134. Lussier-Cacan S, Fortin LJ, Dallongeville J, Davignon J. Effect of fish oil supplementation on plasma homocysteine levels in patients with type III and IV hypertriglyceridemia [Abstract]. Atherosclerosis 1994;109:147
135. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53-60
136. Piolot A, Dubreuil D, Boulet L, Fortin LJ, Davignon J, Lussier-Cacan S. Effect of n-3 polyunsaturated fatty acids on lipid peroxidation, plasma homocysteine levels and antioxidant status in normolipidemic subjects [Abstract]. Atherosclerosis 1995;115(Suppl):S45
137. Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 1990;11:411-6
138. Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria:the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983;309:448-53
139. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, McCully KS. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis 1989;75:1-6
140. Arnadottir M, Brattström L, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993;40:236-40
141. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinimia in humans. J Nutr 1994;124:1927-33
142. Ubbink JB, van der Merwe A, Vermaak WJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993;71:993-8
143. van der Mooren MJ, Wouters GAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24;733-6